Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour

European Journal of Cancer

Volumn 46, Issue 3, 2010, Pages 650-658

  Saito, Yohei ^a,b   Yasunaga, Masahiro ^a   Kuroda, Jun ichiro ^a   Koga, Yoshikatsu ^a   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b Graduate School of Frontier Sciences   (Japan)

Author keywords

DDS (drug delivery system); NK012; Pancreatic cancer; Polymer micelles

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; GEMCITABINE; IRINOTECAN; NK 012; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLUORESCENCE MICROSCOPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MICELLE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE I; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75149138953     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.11.014     Document Type: Article

References (27)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Warshaw A.L., and Fernández-del Castillo C. Pancreatic carcinoma. N Engl J Med 326 (1992) 455-465
3. Wanebo H.J., and Vezeridis M.P. Pancreatic carcinoma in perspective. A continuing challenge. Cancer 78 (1996) 580-591
4. Casper E.S., Green M.R., Kelsen D.P., et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12 (1994) 29-34
5. Carmichael J., Fink U., Russell R.C., et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73 (1996) 101-105
6. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
7. Hosoki T. Dynamic CT of pancreatic tumors. AJR Am J Roentgenol 140 (1983) 959-965
8. Sofuni A., Iijima H., Moriyasu F., et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 40 (2005) 518-525
9. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46 (1986) 6387-6392
10. Li L.H., Fraser T.J., Olin E.J., and Bhuyan B.K. Action of camptothecin on mammalian cells in culture. Cancer Res 32 (1972) 2643-2650
11. Gallo R.C., Whang-Peng J., and Adamson R.H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46 (1971) 789-795
12. Gottlieb J.A., Guarino A.M., Call J.B., Oliverio V.T., and Block J.B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54 (1970) 461-470
13. Muggia F.M., Creaven P.J., Hansen H.H., Cohen M.H., and Selawry O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56 (1972) 515-521
14. Koizumi F., Kitagawa M., Negishi T., et al. Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. Cancer Res 66 (2006) 10048-10056
15. Sumitomo M., Koizumi F., Asano T., et al. Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res 68 (2008) 1631-1635
16. Nakajima T.E., Yasunaga M., Kano Y., et al. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer 122 (2008) 2148-2153
17. Nakajima T.E., Yanagihara K., Takigahira M., et al. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan. Cancer Res 68 (2008) 9318-9322
18. Kuroda J.I., Kuratsu J.I., Yasunaga M., Koga Y., Saito Y., and Matsumura Y. Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int J Cancer 124 (2009) 2505-2511
19. Saito Y., Yasunaga M., Kuroda J., Koga Y., and Matsumura Y. Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer Sci 99 (2008) 1258-1264
20. Koppe M.J., Oyen W.J., Bleichrodt R.P., Verhofstad A.A., Goldenberg D.M., and Boerman O.C. Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biother Radiopharm 21 (2006) 506-514
21. Yang H.M., and Reisfeld R.A. Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice. Proc Natl Acad Sci USA 85 (1988) 1189-1193
22. Kawato Y., Aonuma M., Hirota Y., Kuga H., and Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51 (1991) 4187-4191
23. Muggia F.M. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 3 (2001) 156-162
24. Hassan M., Little R.F., Vogel A., et al. Quantitative assessment of tumor vasculature and response to therapy in kaposi's sarcoma using functional noninvasive imaging. Technol Cancer Res Treat 3 (2004) 451-457
25. Emoto M., Udo T., Obama H., Eguchi F., Hachisuga T., and Kawarabayashi T. The blood flow characteristics in borderline ovarian tumors based on both color Doppler ultrasound and histopathological analyses. Gynecol Oncol 70 (1998) 351-357
26. Kato K, Hamaguchi T, Shirao K et al. Interim analysis of phase I study of NK012, polymer micelle SN-38, in patients with advanced cancer. Proc Am Soc Clin Oncol GI 2008 [Abs #485].
27. Burris HA III, Infante JR, Spigel DR, et al. A phase I dose-escalation study of NK012. Proc Am Soc Clin Oncol 2008 [Abs #2358].